Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis

Purpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of adding atezolizumab to nab-paclitaxel for TNBC from the perspective of Chinese health...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoyan, Lang, Yitian, Liao, Yahui, Zhu, Yizhun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585931/
https://www.ncbi.nlm.nih.gov/pubmed/34778188
http://dx.doi.org/10.3389/fpubh.2021.756899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585931/
https://www.ncbi.nlm.nih.gov/pubmed/34778188
http://dx.doi.org/10.3389/fpubh.2021.756899

Ejemplares similares